Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dimericon Therapeutics
Horgen or Zurich, Zürich, Switzerlandlls.org ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company’s lead compound, based on crosslinked helix dimer technology, is in preclinical development with the goal to advance to IND-ready status for hematological malignancies. No clinical results reported yet; programs are supported by recent seed funding and partnerships.[1][2][4]
- Therapeutic areas
- OncologyHematology
- Modalities
- Crosslinked helix dimers ("Dimericons")Peptidic mimetics of helix dimers[1][2][6]
- Industry
- Biotech
02
Partnerships
Leukemia & Lymphoma Society Therapy Acceleration Program partner/investor[1][4]AbbVie Ventures (investor/partner)[6][8]
Beyond the preview
Go deeper on Dimericon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dimericon Therapeutics.